New studies validate non-invasive methods for diagnosing liver fibrosis and cirrhosis, with enhanced panels showing good diagnostic accuracy and simple markers augmenting performance, offering potential for eliminating the need for liver biopsy in over 80% of cases.
A study of patients with chronic hepatitis C found that silymarin, a popular herbal supplement, had no effect on HCV virus activity or liver inflammation. However, users reported fewer symptoms and improved quality of life compared to non-users.
Patients with chronic hepatitis C infection who use cannabis daily are at higher risk of moderate to severe liver fibrosis. Cannabis use combined with heavy alcohol consumption significantly increases the risk of liver damage. The American Gastroenterological Association recommends avoiding cannabis use in patients with HCV.
Research reveals hereditary hemochromatosis is more prevalent among men with the genetic marker C282Y, posing a significant risk for liver fibrosis and joint disease. The study emphasizes the need for careful clinical assessment to detect the condition in high-risk individuals.
Nucleonics has initiated a Phase 1 human safety study of its experimental treatment NUC B1000, an expressed interfering RNA-based product designed to target and destroy HBV within infected cells. The therapy aims to reduce viral antigen load and potentially resolve viral infection in patients with mild to moderate disease.
The review highlights the importance of carefully planned medical management to optimize outcomes for liver transplantation. Doctors emphasize the need for careful assessment, optimization, and timing for transplantation, leading to high long-term survival rates.
Recent studies have shown that magnetic resonance elastography and other imaging strategies can detect hepatic fibrosis with high sensitivity and specificity. Non-invasive techniques like MRI could replace liver biopsy, which is currently the best way to assess fibrosis but carries serious side effects.
Two new studies found that treating Hepatitis C with peginterferon and ribavirin for shorter durations can yield similar success rates to longer treatments, with cost savings and reduced risk of serious side effects. Patients' HCV-RNA levels after 4 weeks may be an important factor in determining the best treatment length.
Researchers found a founder mutation in two large US families that may contribute to significant colon cancer cases. The mutation increases risk by 2-3 times by age 80, but can be prevented with proper screening and care.
A Phase 2 study found eltrombopag increased platelet counts in 74% of patients with low platelet counts and cirrhosis due to hepatitis C. The drug also allowed more patients to complete antiviral therapy, with 36-65% completing treatment at the lowest and highest doses.
The WIN-R study found weight-based REBETOL plus PEG-INTRON improves sustained virologic response and lowers relapse rates, particularly in African-Americans with genotype 1 HCV. Weight-based dosing is also justified for very heavy patients.
Researchers found that treating patients with psychiatric disorders for hepatitis C yields a sustained viral response without increased risk of side effects. The study suggests using a multidisciplinary team and anti-depressant agents can lessen depressive reactions during treatment.
A study of adolescent offenders found a new upper limit for ALT that is more sensitive for diagnosing liver disease. The findings suggest targeted interventions for at-risk youths, who are high-risk for HCV infection and obesity-related liver disease.
Researchers found that silibinin reduces cancer cell proliferation and enhances programmed death of cancer cells, making it a potential treatment option. The study also suggests that other herbal supplements may have similar anti-tumor effects, warranting further investigation.
Researchers found that a high-fat diet decreases regulatory T cells in the liver, leading to inflammation and increased susceptibility to liver injury. Switching to a normal diet reverses this effect.
A recent study published in Hepatology found that minority patients do not have worse outcomes after liver transplantation when treated at high-volume academic medical centers. The study, led by W. Ray Kim, analyzed data from over 2,800 adult patients and found no relationship between recipient race and survival.
A study published in Clinical Gastroenterology and Hepatology found that minority patients prefer optical colonoscopy (OC) over computed tomographic (CT) colonography for colorectal cancer screening. OC was associated with less discomfort, embarrassment, and pain compared to CT colonography.
Researchers have found promising results with three new non-invasive imaging tests that can diagnose fibrosis and cirrhosis of the liver without a biopsy. Ultrasound-based transient elastography was accurate in identifying patients with cirrhosis, while MR elastography showed nearly 100% accuracy in detecting any degree of liver fibrosis.
A weight-based dosage of ribavirin improved treatment outcomes in patients with chronic hepatitis C, particularly those who are African-American. The study found that response rates increased as body weight increased, suggesting a potential need to tailor dosing to individual patients.
Researchers found that a combined treatment with rapamycin and Gleevec significantly reduced splanchnic neovascularization and portal pressure in rats with established portal hypertension. The combination treatment was more effective than using either drug alone, suggesting a potential new approach for treating human patients.
A recent study suggests that an abnormal amount of inflammatory cells in the duodenum may be responsible for nonulcer dyspepsia, a condition characterized by chronic or recurrent abdominal pain. The researchers propose targeted anti-inflammatory medicine as a potential treatment option.
Researchers discovered that first-degree relatives of PBC patients have a higher prevalence of anti-mitochondrial antibodies, a biomarker indicative of the disease. This finding enables early screening and assessment of high-risk family members through simple blood tests, potentially leading to better outcomes for PBC patients.
A study found that hepatitis C and B virus infections are spreading less quickly among injection drug users in San Francisco. This decrease is attributed to reduced needle-sharing, a common method of transmission.
Non-Caucasian patients with primary biliary cirrhosis have more severe liver disease compared to Caucasian patients. Minority patients reported more limitation of activity, severe itching, and serious complications.
A Japanese patient with liver cirrhosis and HCV infection underwent liver transplantation and was cleared of the virus just one month later. The long-term use of PEGylated IFN may have contributed to this outcome.
A study found that ibuprofen treatment improved cognitive function in rats with chronic liver failure by reducing inflammation and normalizing a key brain pathway. The results suggest a potential therapeutic utility of decreasing inflammation in treating hepatic encephalopathy.
A meta-analysis of 11 studies on coffee consumption and hepatocellular carcinoma (HCC) found a 41% reduction in HCC risk among coffee drinkers. The study suggests that compounds in coffee may act as blocking agents, reducing carcinogenic detoxification and liver disease risk.
Research reveals how microRNA miR-21 helps cancer develop by blocking tumor-suppressor gene PTEN. High levels of miR-21 are found in many kinds of cancer cells, providing a potential marker for patient prognosis.
A recent study discovered a gene variant that significantly increases the risk of developing gallstones, with affected individuals being two to three times more likely to develop the condition. The relevant gene contains instructions for building a molecular pump that transports cholesterol into bile ducts.
Researchers measured the effect of hepatitis B on patients' quality of life, creating a new tool to better assess overall well-being. The study found that psychosocial impact affected many patients more than physical symptoms, underscoring the need for clinicians to consider social and psychological factors in treatment.
Rimonabant reduces liver damage markers, decreases pro-inflammatory proteins, and improves lipid profiles in obese rats. It also normalizes levels of adiponectin, a hormone involved in metabolic disorders.
A new study analyzed predictors of sustained virologic response (SVR) in patients with hepatitis C virus (HCV) infection. The results identified several independent factors that impact SVR, including low levels of HCV in the blood, absence of cirrhosis, and genotype other than genotype 1. Patients treated with pegylated interferon alfa...
A new study found that taking folic acid supplements does not reduce the risk of developing precancerous colon tumors and may even increase it. Researchers also suggest that fortification of grain-based foods with folic acid may be a contributing factor to increased risk.
A new treatment, Sorafenib, has been shown to increase overall survival by over 40% in patients with advanced liver cancer. The study, SHARP, involved 602 patients and found that Sorafenib delays tumor progression and improves survival.
The co-infection of HIV and viral hepatitis is a growing concern, with recent studies showing increasing rates of liver disease and related deaths among those with HIV. Hepatologists are discussing the best approaches to treating these patients, including the use of new agents and consideration of liver transplantation.
Patients with liver cancer undergoing chemotherapy who have high serum levels of hepatitis B virus (HBV) DNA are at risk of developing severe hepatitis, which is associated with poor survival. Researchers found that a pre-chemotherapy HBV viral load above 10^5.65 copies per milliliter was linked to poorer outcomes.
New studies examine factors that affect colonoscopy quality, including age, location, and technician training. Research suggests that competence in efficient colonoscopy requires more than 150 cases, with success rates improving significantly after this threshold.
Researchers have found a significant reduction in the overall colorectal tumor miss rate using advanced colonoscopy technologies, establishing a new benchmark for accurate screening and detection. High levels of C-reactive protein are also associated with increased risk of colorectal adenoma in men, but not in women.
Researchers found that pre-operative CT scans in patients experiencing acute appendicitis symptoms may delay surgery, increasing the risk of appendix rupture. Colonoscopies are recommended over flexible sigmoidoscopy for detecting advanced neoplastic lesions, with notable racial disparities observed.
A recent study evaluated the incidence of malignancy in small pancreatic tumors and identified predictors such as age, gender, symptoms, and radiographic features. The findings suggest that very small tumors with no other symptoms or radiographic indicators have a low risk of malignancy.
Researchers evaluated a new flexible endoscopic suturing method for gastrointestinal perforations and used wireless capsule endoscopy to detect small intestine pathology in young children. The studies found the suturing method to be easy to employ and successful in closing perforations without laparoscopic or open surgery.
Recent research evaluates the progress made to date in diagnosing and treating pancreatic cancer, highlighting promising new applications of technology that will improve survival rates. The studies also identify key predictors of malignancy, including age, gender, symptoms, and radiographic features.
Researchers have discovered that consuming popcorn may lower the risk of diverticulitis by 28% in individuals with diverticular disease. A randomized clinical trial also found rosiglitazone to be an effective treatment for mild-to-moderately active ulcerative colitis.
Researchers at VCU Medical Center report nearly all patients with hepatitis C treated successfully have no detectable virus after seven years. The study validates the use of 'cure' to describe successful treatment, offering hope for those affected by the disease.
Research highlights age-related risks for colon cancer patients undergoing surgery; obesity linked to increased polyp prevalence in women. Racial disparities also affect liver cancer treatment, with African Americans less likely to receive surgical therapy.
Two novel medications, lubiprostone and linaclotide, have shown significant relief from IBS symptoms and constipation. Hypnotherapy has also been found to be effective in treating bowel issues in children.
Researchers found that odorants in spices and fragrances can trigger serotonin release, leading to gastrointestinal reactions. Sacral nerve stimulation has also shown potential for relieving symptoms of idiopathic constipation, with long-term results indicating improved bowel habits and reduced straining.
A study published at Digestive Disease Week found that a lifelong vegetarian diet can reduce the risk of colorectal cancer. Additionally, consuming a fatty soup as an appetizer before dinner may lead to reduced food intake in both lean and obese individuals.
Researchers have made significant advancements in diagnosing and treating chronic hepatitis C, with potential new markers for detecting liver cancer. Studies have also explored the role of autotaxin in linking hepatitis C to hepatocellular carcinoma.
Researchers introduce novel methods for evaluating patients with non-alcoholic fatty liver disease (NAFLD), including a blood test to determine caspase three-generated cytokeratin 18 fragment levels. These tests may help differentiate NASH from simple steatosis and predict treatment outcomes, potentially improving patient care.
New research explores liver biomarkers, disease complications, and novel treatments to improve outcomes in patients with liver disease. A study found that an elevated ALT/AST ratio can predict coronary atherosclerosis in women, independent of metabolic syndrome.
Researchers found that statin therapy improved ALT values in chronic hepatitis C patients with abnormal liver enzymes. The study also showed a higher sustained viral response rate when adding statins to standard peginterferon and ribavirin treatment, suggesting a possible new treatment option.
A study found that liver stiffness measurement by transient elastography can predict severe portal hypertension in patients with hepatitis C-related cirrhosis. The technique is less invasive than traditional methods like HVPG measurement and shows promise for non-invasive diagnosis.
A study of hospitalized patients with cirrhosis and complications of portal hypertension reveals significant racial disparities in treatment, with African-American and Hispanic patients less likely to receive palliative shunts, liver transplants, and prompt endoscopy. These disparities were independent of health insurance status.
Researchers have developed a genetic test that can predict which hepatitis C patients are at high risk of developing cirrhosis. The test uses a 'Cirrhosis Risk Score' based on seven genes and has been validated in independent studies, offering hope for more targeted treatment.
Endoscopic ligation is cost-effective for cirrhotic patients if quality-adjusted life years are considered. Ligation prevents more deaths and episodes, but is not as cost-effective when only life-years are considered.
Researchers at the University of Iowa found that biofeedback treatment can correct bowel function in nearly 80% of patients with dyssynergic defecation. The study compared biofeedback to standard treatment of laxatives, diet, and exercise, and found that biofeedback was significantly more effective in improving muscle function.
Researchers developed a non-invasive method to predict advanced fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) using routine clinical and laboratory values. The study found that age, hyperglycemia, body mass index, platelet count, albumin, and AST/ALT ratio were independent indicators of advanced liver fibrosis.
A new study found that routine colonoscopic surveillance improves survival for colorectal cancer patients. Patients who underwent regular follow-up colonoscopies had better five-year survival rates compared to those who did not receive screenings.
The Model for End-Stage Liver Disease (MELD) is an accurate predictor of liver disease survival, particularly useful in allocating organs for transplants. However, efforts to refine its accuracy are needed to further improve patient outcomes.